Biosimilars

Formerly Cybin, Helus Pharma's Nasdaq launch marks a pivotal shift towards commercializing its breakthrough depression and anxiety drug pipeline.

With its blockbuster drug's patent cliff looming, Merck's leadership faces high stakes at the JPM conference to unveil its strategy for future growth.

Health Canada has approved JERAYGO, the first new hypertension drug class in 30 years, offering a lifeline to patients with hard-to-treat high blood pressure.

A new settlement positions a cost-effective alternative to the blockbuster eye drug Eylea for a 2026 U.S. launch, signaling intense market disruption.

Biotech startup Bio Usawa appoints a world-renowned health expert to lead its access board, betting its entire business model on making advanced drugs affordable.

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.

FDA clears Phase IIb trial for CS1, an epigenetic drug aiming to reverse PAH damage, not just manage symptoms, signaling a major market and patient shift.